RE:RE:RE:RE:RE:RE:This shows how the Financing Market is out thereThere were two financings, craig, one that was announced and closed in May 2019. That was friends of the family helping out, if I recall.
The other was the Boustead Securities, LLC financing. I can't say much about that one except that it crumbled before any real effort was put into it because a legal or policy technicality on the part of the US potential participants.
That was all more than three years ago, just a few months after DrDR became CEO..
There another "friends private placement of $200,000 in January, 2021.
In June of 2021,
the Lind deal was announced. It's worth reading, just for giggles.
Among other things, the press release states, "
This significant financing will enable Bioasis to fully focus on the execution of its business strategy. Importantly, Bioasis now has the means to leverage its existing research in lysosomal dysfunction, neurodegeneration and neuroinflammation and to generate robust licensing packages for potential partners. Whilst there have been challenges in completing certain studies this year, due to constraints at our contract research organizations, these have been overcome and the company is well placed to accomplish its R&D and partnering objectives” said Dr. Deborah Rathjen, Executive Chair of Bioasis."
I wonder how much of that work got done. Or more to the point, how much of it was attempted?
I just don't see any effort on the part of the CEO to avoid this deal. Maybe she thinks it's a good deal. Maybe that's why she didn't seek help from any of us to get an equity financing done to prevent the loss of 90% of the value of xB3. But if she thinks it's a good deal, did she read the fine print?
There have been multiple instances where it was obvious she didn't read the documents before acting. She certainly made roadshows interesting, and scary for some of us, fun for others.
So, yeah, Craig, did you make a point I should address, there, bud? I kind of went off in other directions on you, there.
JD